AbCellera has entered a partnership with Biogen to discover therapeutic antibodies for neurological ailments.

The companies will execute the discovery and development of antibodies for a new target that will aid in offering brain biotherapeutics for neurological indications.

AbCellera will receive an upfront payment from Biogen.

Biogen will also make milestone payments when research programmes meet specific research, developmental and regulatory goals, apart from royalty payments on future net product sales.

AbCellera leverages a new approach to discover antibody drugs to expedite the development of treatment options.

The company's integrated engine combines expertise, technology and data science to advance antibody-based treatments across a range of therapeutic areas.

The collaboration with Biogen leverages AbCellera's expertise in complex challenges in neurological disease.

In November 2023, AbCellera signed a multi-year, multi-programme deal with Prelude Therapeutics.

The collaboration focuses on the discovery, development and marketing of treatments for cancer patients.

Prelude contributes its expertise in targeted protein degradation and AbCellera provides its antibody discovery engine to develop novel precision antibody-drug conjugates.

AbCellera Partnering senior vice-president Murray McCutcheon stated: “Delivering biologics across the blood-brain barrier is one of the most important and long-standing problems in neuroscience.

“We are excited to work with Biogen on this innovative programme, which has the potential to unlock multiple new approaches to treating neurological conditions.”

In September 2023, AbCellera also initiated a strategic collaboration with Incyte, targeting the discovery and development of therapeutic antibodies in oncology.